|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 189.94 USD | +0.09% |
|
-0.31% | +7.01% |
| 01:46pm | Major deals involving U.S. drugmakers and biotechs over the past decade | RE |
| 07:01am | Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy | RE |
| Capitalization | 335B 286B 267B 247B 459B 28,736B 513B 3,194B 1,215B 13,425B 1,257B 1,231B 49,121B | P/E ratio 2025 * |
26.9x | P/E ratio 2026 * | 20.5x |
|---|---|---|---|---|---|
| Enterprise value | 390B 333B 310B 287B 534B 33,406B 597B 3,713B 1,413B 15,607B 1,462B 1,431B 57,105B | EV / Sales 2025 * |
6.51x | EV / Sales 2026 * | 5.88x |
| Free-Float |
96.39% | Yield 2025 * |
3.46% | Yield 2026 * | 3.62% |
More valuation ratios
* Estimated data
More news
Last Transcript: AbbVie Inc.
More recommendations
More press releases
More news
| 1 day | -0.08% | ||
| 1 week | -0.67% | ||
| Current month | +2.07% | ||
| 1 month | +0.16% | ||
| 3 months | +5.35% | ||
| 6 months | +8.16% | ||
| Current year | +6.62% |
| 1 week | 186.67 |  | 193 |
| 1 month | 181.73 | | 193.59 |
| Current year | 164.39 | | 218.66 |
| 1 year | 163.81 | | 218.66 |
| 3 years | 130.96 | | 218.66 |
| 5 years | 79.11 | | 218.66 |
| 10 years | 45.45 | | 218.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 2024-06-30 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 2022-06-22 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 2002-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 2012-12-31 |
William Burnside
BRD | Director/Board Member | 73 | 2012-12-31 |
Edward Rapp
BRD | Director/Board Member | 67 | 2012-12-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 7.12% | 6 M€ | 0.00% | - | |
| 6.85% | 21 M€ | +3.63% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.08% | -0.67% | +12.75% | +23.65% | 335B | ||
| +1.07% | +0.75% | -15.80% | +137.16% | 698B | ||
| -0.13% | -0.01% | +5.77% | -12.79% | 375B | ||
| -1.53% | +0.35% | -54.14% | +9.26% | 313B | ||
| +0.89% | -0.04% | +6.30% | -20.36% | 259B | ||
| -0.16% | -0.89% | +0.47% | +17.53% | 240B | ||
| +0.21% | -0.27% | -13.25% | -7.10% | 217B | ||
| +2.99% | +1.74% | -33.50% | -11.11% | 204B | ||
| -0.60% | -0.78% | -6.77% | +18.86% | 160B | ||
| -0.68% | +0.41% | -8.28% | -51.93% | 146B | ||
| Average | +0.16% | +0.74% | -10.64% | +10.32% | 294.8B | |
| Weighted average by Cap. | +0.26% | +0.50% | -10.80% | +31.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 59.86B 51.13B 47.65B 44.07B 82.02B 5,131B 91.69B 570B 217B 2,397B 225B 220B 8,772B | 64.72B 55.28B 51.52B 47.65B 88.68B 5,548B 99.14B 617B 235B 2,592B 243B 238B 9,484B |
| Net income | 11.59B 9.9B 9.22B 8.53B 15.88B 993B 17.75B 110B 42.01B 464B 43.47B 42.57B 1,698B | 15.37B 13.13B 12.24B 11.32B 21.06B 1,318B 23.55B 146B 55.73B 616B 57.66B 56.47B 2,253B |
| Net Debt | 54.48B 46.54B 43.37B 40.11B 74.65B 4,670B 83.46B 519B 198B 2,182B 204B 200B 7,984B | 45.15B 38.57B 35.94B 33.24B 61.87B 3,871B 69.16B 430B 164B 1,808B 169B 166B 6,616B |
More financial data
* Estimated data
Employees
55,000
Sector
Pharmaceuticals
Calendar
Jul. 14
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-07-09 | 190.25 $ | +0.25% | 2,265,659 |
| 25-07-08 | 189.77 $ | +1.14% | 7,106,896 |
| 25-07-07 | 187.63 $ | -0.87% | 11,049,426 |
| 25-07-03 | 189.28 $ | -0.77% | 3,706,217 |
| 25-07-02 | 190.75 $ | +0.40% | 4,658,511 |
Delayed Quote Nyse, July 09, 2025 at 02:00 pm EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
189.77USD
Average target price
209.12USD
Spread / Average Target
+10.20%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
